Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3907 |
Name | lung squamous cell carcinoma |
Definition | A non-small cell lung carcinoma that has_material_basis_in the squamous cell. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Ponatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 S768R | Dasatinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
DDR2 L63V | Dasatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 L239R | Dasatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 I638F DDR2 T654M | Dasatinib | lung squamous cell carcinoma | decreased response | detail... |
DDR2 I638F | Dasatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 I638F | Ponatinib | lung squamous cell carcinoma | sensitive | detail... |
Unknown unknown | Cisplatin + Gemcitabine + Necitumumab | lung squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Cisplatin + Necitumumab + Pemetrexed Disodium | lung squamous cell carcinoma | not applicable | detail... |
PDGFRA amp | Dasatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 mutant | Dasatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 L239R DDR2 T654M | Dasatinib | lung squamous cell carcinoma | decreased response | detail... |
PDGFRA amp | Imatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 L239R | Ponatinib | lung squamous cell carcinoma | sensitive | detail... |
DDR2 S768R | Dasatinib + Erlotinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
ERBB2 amp | Gefitinib | lung squamous cell carcinoma | resistant | detail... |
FGFR1 amp | Dovitinib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA over exp | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA E545K | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047R | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA over exp | Dactolisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA E545K | Dactolisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047R | Dactolisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA H1047R | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA E545K | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA over exp | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
FGFR1 amp | RO4987655 | lung squamous cell carcinoma | no benefit | detail... |
FGFR1 amp | RO5126766 | lung squamous cell carcinoma | no benefit | detail... |
FGFR1 amp | Selumetinib | lung squamous cell carcinoma | no benefit | detail... |
HRAS Q61L | Selumetinib | lung squamous cell carcinoma | sensitive | detail... |
HRAS Q61L | Buparlisib | lung squamous cell carcinoma | no benefit | detail... |
HRAS Q61L | Everolimus + Selumetinib | lung squamous cell carcinoma | sensitive | detail... |
HRAS Q61L | Binimetinib + Everolimus | lung squamous cell carcinoma | sensitive | detail... |
HRAS Q61L | AZD8055 + Binimetinib | lung squamous cell carcinoma | sensitive | detail... |
FGFR1 amp | Infigratinib | lung squamous cell carcinoma | sensitive | detail... |
Unknown unknown | Docetaxel + Trametinib | lung squamous cell carcinoma | not applicable | detail... |
FGFR1 amp | AZD4547 + Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
FGFR3 positive | Rogaratinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
FGFR1 amp | AZD4547 | lung squamous cell carcinoma | no benefit | detail... |
ERBB2 mutant | Afatinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
ERBB4 mutant | Afatinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | Prexasertib | lung squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + Paclitaxel + Pembrolizumab | lung squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + Nab-paclitaxel + Pembrolizumab | lung squamous cell carcinoma | not applicable | detail... |
PIK3CA amp | Buparlisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA act mut | Buparlisib | lung squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA E545K PIK3CA amp | Buparlisib | lung squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA E542K PIK3CA amp | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
PIK3CA act mut | Alpelisib | lung squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA E542K PIK3CA amp | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
CDKN2A loss PIK3CA act mut | Buparlisib + Palbociclib | lung squamous cell carcinoma | predicted - sensitive | detail... |
CDKN2A loss PIK3CA E545K PIK3CA amp | Buparlisib + Palbociclib | lung squamous cell carcinoma | sensitive | detail... |
CDKN2A loss PIK3CA E542K PIK3CA amp | Buparlisib + Palbociclib | lung squamous cell carcinoma | sensitive | detail... |
ERBB2 S310Y | Afatinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
FGFR1 amp | Debio 1347 | lung squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA mutant | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA E545K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA E542K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA H1047R | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA N345K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA E453K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA G1049R | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA M1043I | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
DDR2 L239R DDR2 T654I | Dasatinib | lung squamous cell carcinoma | predicted - resistant | detail... |
Unknown unknown | CX-2029 | lung squamous cell carcinoma | not applicable | detail... |
CDKN2A loss | Palbociclib | lung squamous cell carcinoma | predicted - sensitive | detail... |
PIK3CA mutant | Capivasertib | lung squamous cell carcinoma | no benefit | detail... |
PIK3CA amp | Capivasertib | lung squamous cell carcinoma | no benefit | detail... |
Unknown unknown | Cisplatin + Paclitaxel + Tislelizumab | lung squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + Paclitaxel + Tislelizumab | lung squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Cisplatin + Gemcitabine + Tislelizumab | lung squamous cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + Gemcitabine + Tislelizumab | lung squamous cell carcinoma | not applicable | detail... |
FGFR1 amp | Carboplatin + GSK3052230 + Paclitaxel | lung squamous cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | Carboplatin + Lumretuzumab + Paclitaxel | lung squamous cell carcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Recruiting | USA | 2 |
NCT01737502 | Phase Ib/II | Auranofin + Sirolimus | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01741727 | Phase II | Depatuxizumab mafodotin | A Study of ABT-414 in Subjects With Solid Tumors | Completed | USA | CAN | 0 |
NCT01820325 | Phase II | Buparlisib | Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | Terminated | USA | CAN | 3 |
NCT01877811 | Phase Ib/II | RXDX-105 | CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 | Completed | USA | 0 |
NCT01948141 | Phase II | Nintedanib | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | Completed | USA | 0 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | 6 |
NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | 4 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Recruiting | USA | 1 |
NCT02403895 | Phase II | Vistusertib Paclitaxel | AZD2014 and Weekly Paclitaxel in Squamous NSCLC | Terminated | USA | 2 |
NCT02417701 | Phase II | Sapanisertib | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | Completed | USA | 0 |
NCT02443337 | Phase II | Necitumumab LY3023414 | A Study of LY3023414 and Necitumumab in Squamous Lung Cancer | Terminated | USA | 0 |
NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02513563 | Phase II | Carboplatin + Paclitaxel Adavosertib | AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | Recruiting | USA | 0 |
NCT02536495 | Phase Ib/II | Docetaxel Selinexor | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | Withdrawn | 0 | |
NCT02785913 | Phase II | Taselisib | Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | Completed | USA | CAN | 0 |
NCT02785939 | Phase II | Palbociclib | Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | Active, not recruiting | USA | 0 |
NCT02785952 | Phase III | Nivolumab Ipilimumab + Nivolumab | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Active, not recruiting | USA | CAN | 0 |
NCT02924233 | Phase Ib/II | Nivolumab + SYM004 Nivolumab | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
NCT03157089 | Phase II | Afatinib + Pembrolizumab | Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO) | Completed | USA | 4 |
NCT03178552 | Phase II | Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib | A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) | Recruiting | USA | CAN | 26 |
NCT03215706 | Phase III | Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) | Active, not recruiting | USA | CAN | 17 |
NCT03234712 | Phase I | ABBV-321 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Active, not recruiting | USA | 2 |
NCT03261947 | Phase II | TAK-931 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |
NCT03377556 | Phase II | Talazoparib | Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03409614 | Phase III | Cemiplimab + Ipilimumab Cemiplimab | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Active, not recruiting | USA | 18 |
NCT03441100 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin IMA202 | TCR-engineered T Cells in NSCLC and HCC Patients | Recruiting | USA | 1 |
NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
NCT03574753 | Phase II | Telisotuzumab vedotin | Lung-MAP S1400K: c-MET Positive | Active, not recruiting | USA | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | USA | CAN | 2 |
NCT03976362 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Olaparib + Pembrolizumab | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | Recruiting | USA | CAN | 18 |
NCT03976375 | Phase III | Lenvatinib Lenvatinib + Pembrolizumab Docetaxel | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | Recruiting | USA | CAN | 16 |
NCT04033354 | Phase III | Carboplatin + Nab-paclitaxel + Serplulimab Carboplatin + Nab-paclitaxel | A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC | Recruiting | USA | 1 |
NCT04043195 | Phase Ib/II | Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) | Recruiting | USA | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Recruiting | USA | 0 |
NCT04145622 | Phase Ib/II | DS-7300a | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Recruiting | USA | 0 |
NCT04262856 | Phase II | AB154 + AB928 + GLS-010 GLS-010 AB154 + GLS-010 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) | Recruiting | USA | 5 |
NCT04266730 | Phase I | PANDA-VAC + Pembrolizumab + Poly ICLC | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) | Not yet recruiting | USA | 0 |
NCT04350463 | Phase II | CC-90011 + Nivolumab | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | Recruiting | USA | 5 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Recruiting | USA | 3 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Recruiting | USA | 0 |
NCT04497584 | Phase II | Afatinib + Prednisone | Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC | Not yet recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |